Form 4: Intellia Therapeutics Director Frank Verwiel Reports Significant Equity Grant and Stock Option Acquisition

Intellia Therapeutics, Inc. Director Frank Verwiel reported the acquisition of 8,000 restricted stock units and stock options for 11,450 shares, increasing his beneficial ownership in the company.

Summary

• Director Frank Verwiel acquired 8,000 shares of Intellia Therapeutics, Inc. common stock through a grant of restricted stock units (RSUs) on June 11, 2025.
• These RSUs represent a contingent right to receive one share of common stock for each unit, with an acquisition price of $0.00.
• Following this transaction, Mr. Verwiel directly beneficially owns 25,948 shares of common stock.
• Additionally, Mr. Verwiel was granted stock options to purchase 11,450 shares of common stock at an exercise price of $8.37 per share on June 11, 2025.
• These stock options expire on June 10, 2035, and vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• Mr. Verwiel directly beneficially owns 11,450 derivative securities (stock options) following this transaction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director receiving equity compensation, aligning their interests with shareholders. There are no negative financial implications or red flags, and the transaction is routine.

Positives

• The acquisition of 8,000 restricted stock units and 11,450 stock options by a director indicates continued alignment of management's interests with shareholders.
• The grant of RSUs at a $0.00 price and stock options at $8.37 suggests these are part of a compensation package, which is a common practice to incentivize directors and align their long-term interests with the company's performance.

Risks

• The Limited Power of Attorney includes an indemnification clause where the undersigned (Frank Verwiel) agrees to indemnify the attorney-in-fact and the Company against any demand, damage, loss, cost, or expense arising from any false or misleading information provided by the undersigned. This highlights a compliance risk related to the accuracy of information provided by the reporting person for SEC filings.

Future Outlook

The document primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details an equity grant to a director, which is a standard practice in the biotechnology and pharmaceutical industries to align executive and director incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially incentivizing long-term value creation and demonstrating confidence in the company's future.

Next Steps

• The stock options granted on June 11, 2025, will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Recommendation

Keywords

Intellia Therapeutics, NTLA, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, Frank Verwiel, Equity Grant